Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Impact BioMedical, Inc. ( (IBO) ) has provided an announcement.
On February 27, 2026, Impact BioMedical, Inc. and its transaction partners amended their June 21, 2025 Merger and Share Exchange Agreement with Dr Ashleys Bio Labs Limited to adjust how PubCo shares will be allocated at closing. PubCo will still issue 169,560,000 ordinary shares as Company Share Consideration, but 22,000 compensation shares for Impact’s CEO and up to 128,000 shares for DSS, Inc. will now be deducted from the Dr Ashleys shareholder’s portion, while the deal’s outside termination date was pushed from March 31, 2026 to July 1, 2026 and Impact was required to seek board approval for certain loan agreements.
The parties also amended the Voting and Support Agreement on February 27, 2026 to update that supporting stockholders now hold 92,980,843 Impact common shares, or about 88.87% on a fully diluted basis, and revised ownership schedules for DSS, Inc. and DSS BioHealth Security, Inc. In a parallel amendment to the Transition Arrangement Agreement, DSS agreed to new funding and hold harmless obligations for the merger, in return for 53,000 PubCo shares upon closing and a further 75,000 shares upon full performance, both registered and tradable, reinforcing DSS’s role as a key financial backer and tightening the alignment of incentives among Impact, DSS, and the Dr Ashleys stakeholder group.
More about Impact BioMedical, Inc.
Impact BioMedical, Inc., a Nevada corporation, operates in the biomedical and life sciences sector, focusing on developing and commercializing healthcare and bio-based technologies. The company’s capital structure and strategic direction are closely tied to corporate transactions with affiliates such as DSS, Inc. and Dr Ashleys Bio Labs Limited, reflecting an emphasis on mergers, share exchanges, and structured funding arrangements.
Average Trading Volume: 107,558
Technical Sentiment Signal: Sell
Learn more about IBO stock on TipRanks’ Stock Analysis page.